[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumor-induced-osteomalacia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumor-induced-osteomalacia":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100621090",false,"NCT07366099","Al18F-NOTA-LM3 PET\u002FCT in Patients With TIO","Application of Al18F-NOTA-LM3 PET\u002FCT in the Diagnosis and Evaluation of Tumor-Induced Osteomalacia","Inclusion Criteria:\n\n* Patients aged 18 to 80 years.\n* Suspected or confirmed TIO patients.\n\nExclusion Criteria:\n\n* Combined with other types of tumors.\n* Severe liver or renal dysfunction (ALT\u002FAST≥5 ULN, GFR\\\u003C30ml\u002Fmin).\n* Pregnant or breast-feeding women.\n* Inability to perform PET\u002FCT scans.","ALL","18 Years","80 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET\u002FCT in patients with tumor-induced osteomalacia.",[26],"Tumor-Induced Osteomalacia","RECRUITING","2026-01-18",{"date":30,"type":31},"2026-01-26","ACTUAL",{"date":33,"type":31},"2023-03-30",{"date":35,"type":20},"2026-05-30",{"name":37,"class":38},"Peking Union Medical College Hospital","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":4,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":45,"phases":4,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":58,"locationsCount":4},"100345245","NCT03775187","Expanded Access to Burosumab","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","Individual patient expanded access requests may be considered for patients who have no other treatment options",[48,26],"X-linked Hypophosphatemia",[50,51,52,53],"Expanded Access","Compassionate Use","XLH","TIO","AVAILABLE","2025-02-28",{"date":57,"type":31},"2025-03-05",{"name":59,"class":60},"Kyowa Kirin Co., Ltd.","INDUSTRY",""]